These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8001030)

  • 21. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma.
    Bafaloukos D; Fountzilas G; Skarlos D; Pavlidis N; Bakoyiannis C; Karvounis N; Kosmidis P
    Oncology; 1998; 55(1):48-52. PubMed ID: 9428375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
    Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
    Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
    Proebstle TM; Scheibenbogen C; Sterry W; Keilholz U
    Eur J Cancer; 1996 Aug; 32A(9):1530-3. PubMed ID: 8911113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.
    Antoine EC; Benhammouda A; Bernard A; Youssef A; Mortier N; Gozy M; Nizri D; Auclerc G; Rocher MA; Soubrane CL; Weil M; Khayat D
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S16-21. PubMed ID: 9457388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
    Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P
    J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
    Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
    Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial.
    Li S; Wu X; Chen P; Pei Y; Zheng K; Wang W; Qiu E; Zhang X
    Anticancer Drugs; 2019 Apr; 30(4):402-409. PubMed ID: 30664008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
    Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR
    J Clin Oncol; 1993 Oct; 11(10):1969-77. PubMed ID: 8410122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histamine in cancer immunotherapy.
    Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
    Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.
    Jansen RL; Slingerland R; Goey SH; Franks CR; Bolhuis RL; Stoter G
    J Immunother (1991); 1992 Jul; 12(1):70-3. PubMed ID: 1322167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
    Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
    Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
    Gorbonova VA; Egorov GN; Perevodchikova NI; Orel NF
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():310-4. PubMed ID: 10939991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.